Apoptosis-modulating drugs for improved cancer therapy

European Surgical Research

Volumn 48, Issue 3, 2012, Pages 111-120

  Ocker, M ^a   Hopfner M ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Autophagy; Endoplasmic reticulum stress; Necroptosis; Unfolded protein response

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AEG 35156; ANTIBODY; AZD 8055; BORTEZOMIB; CONATUMUMAB; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DECOY RECEPTOR 2; DECOY RECEPTOR 3; DROZITUMAB; DULANERMIN; FAS ANTIGEN; FAS LIGAND; GATAPARSEN; GOSSYPOL; ISOSORBIDE; LEXATUMUMAB; MAPATUMUMAB; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PANOBINOSTAT; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; TANESPIMYCIN; TIGATUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; APOPTOSIS; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE PROGRESSION; COLORECTAL CANCER; DNA REPLICATION; DRUG EFFICACY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; HUMAN; LUNG NON SMALL CELL CANCER; MITOSIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR CELL; UNFOLDED PROTEIN RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; DRUG RESISTANCE, NEOPLASM; HUMANS; NECROSIS; NEOPLASMS;

EID: 84860168136     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000336875     Document Type: Review

References (161)

1. Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
2. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
3. Gieseler F, Rudolph P, Kloeppel G, Foelsch UR: Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail? Int J Colorectal Dis 2003; 18: 470-480. (Pubitemid 37265858)
4. Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275-292. (Pubitemid 40227997)
5. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ: Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011; 108: 1556-1563.
6. Garrett CR, Eng C: Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 2011; 11: 937-949.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
8. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
9. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
10. Platini F, Perez-Tomas R, Ambrosio S, Tessitore L: Understanding autophagy in cell death control. Curr Pharm Des 2010; 16: 101-113.
11. Amaravadi RK, Thompson CB: The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007; 13: 7271-7279.
12. Yang Z, Klionsky DJ: Eaten alive: a history of macroautophagy. Nat Cell Biol 2010; 12: 814-822.
13. Galluzzi L, Kroemer G: Necroptosis: a specialized pathway of programmed necrosis. Cell 2008; 135: 1161-1163.
14. Vakifahmetoglu H, Olsson M, Zhivotovsky B: Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008; 15: 1153-1162. (Pubitemid 351850968)
15. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23: 2825-2837. (Pubitemid 38638845)
16. Gupta S: Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 2001; 69: 2957-2964.
17. Jin Z, El-Deiry WS: Overview of cell death signaling pathways. Cancer Biol Ther 2005; 4: 139-163. (Pubitemid 41351311)
18. Savill J, Fadok V: Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784-788.
19. Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ 2003; 10: 45-65. (Pubitemid 36511832)
20. Baud V, Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11: 372-377. (Pubitemid 32900529)
21. Sayers TJ: Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 2011; 60: 1173-1180.
22. Peter ME, Krammer PH: The CD95(Apo-1/ Fas) disc and beyond. Cell Death Differ 2003; 10: 26-35.
23. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of death receptor signals by cellular flip. Nature 1997; 388: 190-195. (Pubitemid 27297457)
24. Ashkenazi A, Herbst RS: To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008; 118: 1979-1990. (Pubitemid 351872316)
25. Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656. (Pubitemid 37328916)
26. Giam M, Huang DC, Bouillet P: BH3-only proteins and their roles in programmed cell death. Oncogene 2008; 27(suppl 1):S128-S136.
27. Zamzami N, Kroemer G: The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001; 2: 67-71. (Pubitemid 33676964)
28. Green DR, Kroemer G: The pathophysiology of mitochondrial cell death. Science 2004; 305: 626-629. (Pubitemid 39006738)
29. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for DATP and cytochrome c. Cell 1996; 86: 147-157. (Pubitemid 26256586)
30. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR: The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2000; 2: 156-162.
31. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein homologous to C. elegans ced-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405-413. (Pubitemid 27347231)
32. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and DATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489. (Pubitemid 27508237)
33. Yuan S, Yu X, Topf M, Ludtke SJ, Wang X, Akey CW: Structure of an apoptosome-procaspase-9 card complex. Structure 2010; 18: 571-583.
34. 2+: a control point for apoptosis. Science 2003; 300: 135-139.
35. Elyaman W, Terro F, Suen KC, Yardin C, Chang RC, Hugon J: Bad and Bcl-2 regulation are early events linking neuronal endoplasmic reticulum stress to mitochondria-mediated apoptosis. Brain Res Mol Brain Res 2002; 109: 233-238. (Pubitemid 36078390)
36. Ferri KF, Kroemer G: Organelle-specific initiation of cell death pathways. Nat Cell Biol 2001; 3:E255-E263.
37. Rodriguez D, Rojas-Rivera D, Hetz C: Integrating stress signals at the endoplasmic reticulum: the Bcl-2 protein family rheostat. Biochim Biophys Acta 2011; 1813: 564-574.
38. Zhivotovsky B, Orrenius S: Calcium and cell death mechanisms: a perspective from the cell death community. Cell Calcium 2011; 50: 211-221.
39. Walter P, Ron D: The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334: 1081-1086.
40. Haze K, Yoshida H, Yanagi H, Yura T, Mori K: Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell 1999; 10: 3787-3799. (Pubitemid 29534025)
41. Shen J, Chen X, Hendershot L, Prywes R: ER stress regulation of ATF6 localization by dissociation of BIP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell 2002; 3: 99-111. (Pubitemid 34778399)
42. Ron D, Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-529. (Pubitemid 46985379)
43. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, Yuan J: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403: 98-103. (Pubitemid 30038529)
44. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D: Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 2000; 5: 897-904.
45. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, Ron D: Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000; 287: 664-666. (Pubitemid 30070916)
46. Park HH, Lo YC, Lin SC, Wang L, Yang JK, Wu H: The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu Rev Immunol 2007; 25: 561-586. (Pubitemid 46697917)
47. Slee EA, Adrain C, Martin SJ: Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ 1999; 6: 1067-1074.
48. Degterev A, Boyce M, Yuan J: A decade of caspases. Oncogene 2003; 22: 8543-8567. (Pubitemid 38028527)
49. Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501. (Pubitemid 28391865)
50. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ: Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274: 1156-1163.
51. Ku NO, Liao J, Omary MB: Apoptosis generates stable fragments of human type I keratins. J Biol Chem 1997; 272: 33197-33203. (Pubitemid 28023666)
52. Caulin C, Salvesen GS, Oshima RG: Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 1997; 138: 1379-1394. (Pubitemid 27415063)
53. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF: Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001; 3: 339-345. (Pubitemid 32288440)
54. Janicke RU, Walker PA, Lin XY, Porter AG: Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 1996; 15: 6969-6978. (Pubitemid 27023268)
55. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM, Ross R: Cleavage of p21CIP1/WAF1 and p27KIP1 mediates apoptosis in endothelial cells through activation of CDK2: role of a caspase cascade. Mol Cell 1998; 1: 553-563. (Pubitemid 128374691)
56. Tang D, Kidd VJ: Cleavage of DFF-45/ICAD by multiple caspases is essential for its function during apoptosis. J Biol Chem 1998; 273: 28549-28552. (Pubitemid 28507533)
57. Sakahira H, Enari M, Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998; 391: 96-99. (Pubitemid 28079223)
58. Altieri DC: Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010; 430: 199-205.
59. Gyrd-Hansen M, Meier P: IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
60. Wei Y, Fan T, Yu M: Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 278-288. (Pubitemid 351572108)
61. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999; 18: 5242-5251. (Pubitemid 29465575)
62. Darding M, Meier P: IAPs: Guardians of RIPK1. Cell Death Differ 2012; 19: 58-66.
63. Oppenheim RW, Flavell RA, Vinsant S, Prevette D, Kuan CY, Rakic P: Programmed cell death of developing mammalian neurons after genetic deletion of caspases. J Neurosci 2001; 21: 4752-4760. (Pubitemid 32565633)
64. Edinger AL, Thompson CB: Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004; 16: 663-669. (Pubitemid 39463117)
65. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, Yuan J: Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-1323.
66. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G: Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714.
67. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J: Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112-119.
68. Temkin V, Huang Q, Liu H, Osada H, Pope RM: Inhibition of ADP/ATP exchange in receptor-interacting protein-mediated necrosis. Mol Cell Biol 2006; 26: 2215-2225. (Pubitemid 43346922)
69. Degterev A, Yuan J: Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 2008; 9: 378-390. (Pubitemid 351574200)
70. Green DR, Oberst A, Dillon CP, Weinlich R, Salvesen GS: RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. Mol Cell 2011; 44: 9-16.
71. Oberstein A, Jeffrey PD, Shi Y: Crystal structure of the BCL-XL-beclin 1 peptide complex: beclin 1 is a novel BH3-only protein. J Biol Chem 2007; 282: 13123-13132. (Pubitemid 47100641)
72. He C, Klionsky DJ: Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009; 43: 67-93.
73. Eskelinen EL: New insights into the mechanisms of macroautophagy in mammalian cells. Int Rev Cell Mol Biol 2008; 266: 207-247.
74. Ullman E, Fan Y, Stawowczyk M, Chen HM, Yue Z, Zong WX: Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress. Cell Death Differ 2008; 15: 422-425.
75. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, Tsujimoto Y: Role of BCL-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004; 6: 1221-1228. (Pubitemid 39625121)
76. Baehrecke EH: Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 2005; 6: 505-510.
77. Fazi B, Bursch W, Fimia GM, Nardacci R, Piacentini M, Di Sano F, Piredda L: Fenretinide induces autophagic cell death in caspase-defective breast cancer cells. Autophagy 2008; 4: 435-441. (Pubitemid 351705140)
78. Simpson CD, Anyiwe K, Schimmer AD: Anoikis resistance and tumor metastasis. Cancer Lett 2008; 272: 177-185.
79. Ozden SA, Ozyurt H, Ozgen Z, Kilinc O, Oncel M, Gul AE, Karadayi N, Serakinci N, Kan B, Orun O: Prognostic role of sensitive-to-apoptosis gene expression in rectal cancer. World J Gastroenterol 2011; 17: 4905-4910.
80. Chen MK, Lai JC, Chang CC, Chang JH, Chang YJ, Chen HC: Prognostic impact of Bcl-2 expression on advanced nasopharyngeal carcinoma. Head Neck 2008; 30: 1052-1057.
81. Callagy GM, Webber MJ, Pharoah PD, Caldas C: Meta-analysis confirms Bcl2 is an independent prognostic marker in breast cancer. BMC Cancer 2008; 8: 153.
82. Bria E, Visca P, Novelli F, Casini B, Diodoro MG, Perrone-Donnorso R, Botti C, Sperduti I, Facciolo F, Milella M, Cecere FL, Cognetti F, Mottolese M: Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. Eur J Surg Oncol 2008; 34: 593-598. (Pubitemid 351514886)
83. Okumura M, Kajiyama Y, Takeda K, Okumura K, Tsurumaru M: Correlation between loss of Bcl-xL expression and improved prognosis in advanced esophageal cancer treated by preoperative chemoradiotherapy. Eur Surg Res 2008; 41: 260-266.
84. Nagata M, Nakayama H, Tanaka T, Yoshida R, Yoshitake Y, Fukuma D, Kawahara K, Nakagawa Y, Ota K, Hiraki A, Shinohara M: Overexpression of cIAP2 contributes to 5-FU resistance and a poor prognosis in oral squamous cell carcinoma. Br J Cancer 2011; 105: 1322-1330.
85. Kim MA, Lee HE, Lee HS, Yang HK, Kim WH: Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma. Virchows Arch 2011; 459: 503-510.
86. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M, Coggi G, Bosari S: Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer 2009; 9: 125.
87. Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Oh YT, Chun M, Kim JH, Sheen SS, Lim HY: Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 2007; 13: 4146-4153. (Pubitemid 47105977)
88. Pluta P, Cebula-Obrzut B, Ehemann V, Pluta A, Wierzbowska A, Piekarski J, Bilski A, Nejc D, Kordek R, Robak T, Smolewski P, Jeziorski A: Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 2011; 58: 430-435.
89. Mizutani Y, Katsuoka Y, Bonavida B: Prognostic significance of second mitochondria-derived activator of caspase (Smac/ DIABLO) expression in bladder cancer and target for therapy. Int J Oncol 2010; 37: 503-508.
90. Zlobec I, Minoo P, Baker K, Haegert D, Khe tani K, Tornillo L, Terracciano L, Jass JR, Lugli A: Loss of Apaf-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer 2007; 43: 1101-1107. (Pubitemid 46486708)
91. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK: Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 2011; 117: 1172-1182.
92. Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, Reiche JA, Hermeking H, Rizzani A, Bruns CJ, Kolligs FT, Kirchner T, Goke B, De Toni EN: Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 2010; 16: 5529-5538.
93. Martinez R, Setien F, Voelter C, Casado S, Quesada MP, Schackert G, Esteller M: CPG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007; 28: 1264-1268. (Pubitemid 47062686)
94. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241. (Pubitemid 27456390)
95. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321. (Pubitemid 28524494)
96. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 1999; 96: 857-868. (Pubitemid 29165088)
97. Castedo M, Ferri KF, Kroemer G: Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002; 9: 99-100. (Pubitemid 34144768)
98. Furuta S, Hidaka E, Ogata A, Yokota S, Kamata T: Ras is involved in the negative control of autophagy through the class I PI3-kinase. Oncogene 2004; 23: 3898-3904. (Pubitemid 38747918)
99. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O'Kane CJ, Rubinsztein DC: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36: 585-595. (Pubitemid 38715985)
100. Wiezorek J, Holland P, Graves J: Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16: 1701-1708.
101. Kaplan-Lefko PJ, Graves JD, Zoog SJ, Pan Y, Wall J, Branstetter DG, Moriguchi J, Coxon A, Huard JN, Xu R, Peach ML, Juan G, Kaufman S, Chen Q, Bianchi A, Kordich JJ, Ma M, Foltz IN, Gliniak BC: Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther 2010; 9: 618-631.
102. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, Fujiwara K: A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 2008; 19: 1060-1067. (Pubitemid 351796330)
103. Zhang L, Zhang X, Barrisford GW, Olumi AF: Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DRr5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251: 146-157. (Pubitemid 46589773)
104. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D: A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010; 16: 1256-1263.
105. Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, Boku N, Onozawa Y, Hsu CP, Gorski KS, Friberg G, Kawaguchi T, Sasaki T: Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68: 733-741.
106. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, Lo-Russo PM: A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 2010; 16: 5883-5891.
107. Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo FR, Wojtowicz-Praga S, Percent I, Saleh M: Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010; 25: 13-19.
108. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW: Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010; 21: 376-381.
109. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, Barrett M, Judson I, Kaye S, Fox NL, Halpern W, Corey A, Calvert H, de Bono J: Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13: 6187-6194. (Pubitemid 350075080)
110. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25: 1390-1395. (Pubitemid 46706887)
111. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61: 82-90.
112. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM: A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 3450-3455.
113. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG: Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27: 4413-4421.
114. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S: Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102: 506-512.
115. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
116. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28: 2839-2846.
117. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E, Pujol JL, Kozielski J, Baker N, Smethurst D, Hei YJ, Ashkenazi A, Stern H, Amler L, Pan Y, Blackhall F: Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4442-4451.
118. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY: The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007; 67: 4981-4988. (Pubitemid 46910207)
119. Thorpe JA, Christian PA, Schwarze SR: Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 2008; 68: 200-209. (Pubitemid 351186232)
120. Kandasamy K, Kraft AS: Proteasome inhibitor PS-341 (Velcade) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region. Mol Cancer Ther 2008; 7: 1091-1100.
121. Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA, Schimmer AD: Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther 2010; 9: 246-256.
122. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A, Teufel A, Worns M, Fischer T, Strand S, Lohse AW, Galle PR: Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and trail receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006; 15: 227-230.
123. Chonghaile TN, Letai A: Mimicking the BH3 domain to kill cancer cells. Oncogene 2008; 27(suppl 1):S149-S157.
124. Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-1132.
125. Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to Bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 1997; 281: 420-427. (Pubitemid 27203096)
126. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD: Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 2000; 6: 2891-2902. (Pubitemid 30482132)
127. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H: Chemosensitisation of malignant melanoma by Bcl2 antisense therapy. Lancet 2000; 356: 1728-1733.
128. Tolcher AW: Preliminary phase I results of G3139 (Bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 2001; 28: 67-70.
129. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR: Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114-1120. (Pubitemid 46596764)
130. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri LM, Rai KR: 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27: 5208-5212.
131. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G: Modulation of malignant B cell activation and apoptosis by Bcl-2 antisense ODN and immunostimulatory CPG ODN. J Leukoc Biol 2002; 72: 83-92.
132. Okamoto K, Murawaki Y: The therapeutic potential of RNA interference: novel approaches for cancer treatment. Curr Pharm Biotechnol 2011, E-pub ahead of print.
133. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D: Variants of Bcl-2 specific siRNA for silencing antiapoptotic Bcl-2 in pancreatic cancer. Gut 2005; 54: 1298-1308. (Pubitemid 41192493)
134. Okamoto K, Ocker M, Neureiter D, Dietze O, Zopf S, Hahn EG, Herold C: Bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 2007; 11: 349-361. (Pubitemid 46693333)
135. Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Viallet J, Marshall JL: Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010; 16: 4038-4045.
136. Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM: A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011; 74: 481-485.
137. Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM: A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol 2010; 66: 1079-1085.
138. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C: Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 2001; 66: 239-248. (Pubitemid 32675026)
139. Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ: Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 2010; 5: 1637-1643.
140. Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, Wood BA, Leopold L: Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 2011; 6: 781-785.
141. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
142. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM: Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916.
143. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA: Navitoclax, a targeted highaffinity inhibitor of Bcl-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
144. Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, Fairbrother WJ, Sampath D, Belmont LD: Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 2011; 17: 1394-1404.
145. Wang G, Zhan Y, Wang H, Li W: ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic
146. Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, Shoemaker AR, Tahir SK, Zhang H, Ackler SL, Rosenberg SH, Maecker H, Sampath D, Leverson JD, Tse C, Elmore SW: The Bcl-2/Bcl-xL/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 2011; 10: 2340-2349.
147. Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, Mc-Conkey DJ: Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005; 65: 11510-11519. (Pubitemid 41821709)
148. Taiyab A, Sreedhar AS, Rao ChM: Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. Biochem Pharmacol 2009; 78: 142-152.
149. Di Fazio P, Ocker M, Montalbano R: New drugs, old fashioned ways: ER stress induced cell death. Curr Pharm Biotechnol 2011, E-pub ahead of print.
150. Di Fazio P, Schneider-Stock R, Neureiter D, Okamoto K, Wissniowski T, Gahr S, Quint K, Meissnitzer M, Alinger B, Montalbano R, Sass G, Hohenstein B, Hahn EG, Ocker M: The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol 2010; 32: 285-300.
151. Ocker M: Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem 2010; 1: 55-61.
152. Apel A, Zentgraf H, Buchler MW, Herr I: Autophagy - a double-edged sword in oncology. Int J Cancer 2009; 125: 991-995.
153. Yang ZJ, Chee CE, Huang S, Sinicrope FA: The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011; 10: 1533-1541.
154. Han W, Sun J, Feng L, Wang K, Li D, Pan Q, Chen Y, Jin W, Wang X, Pan H, Jin H: Autophagy inhibition enhances daunorubicin- induced apoptosis in K562 cells. PLoS One 2011; 6:e28491.
155. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, Wang XY, Dai Z, Peng YF, Gu CY, Qiu SJ, Fan J: Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 2011; 7: 1159-1172.
156. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, Kaneko M, Kitayama J, Takahashi K, Nagawa H: Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010; 10: 370.
157. Chen DJ, Huerta S: Smac mimetics as new cancer therapeutics. Anticancer Drugs 2009; 20: 646-658.
158. Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T: Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011; 68: 505-511.
159. Talbot DC, Ranson M, Davies J, Lahn M, Callies S, Andre V, Kadam S, Burgess M, Slapak C, Olsen AL, McHugh PJ, de Bono JS, Matthews J, Saleem A, Price P: Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010; 16: 6150-6158.
160. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M: Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009; 27: 4741-4746.
161. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC: Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011; 10: 35.